GPNMB expression in uveal melanoma: A potential for targeted therapy

Melanoma Research

Volumn 20, Issue 3, 2010, Pages 184-190

  Williams, Michelle D ^a   Esmaeli, Bita ^b   Soheili, Aydin ^b   Simantov, Ronit ^d   Gombos, Dan S ^b   Bedikian, Agop Y ^c   Hwu, Patrick ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Department of Head and Neck Surgery   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CURAGEN CORPORATION   (United States)

Author keywords

CDX 011 (glembatumumab vedotin); Glycoprotein NMB; Immunohistochemistry; Metastases; Uveal melanoma

Indexed keywords

GLEMBATUZUMAB VEDOTIN; GLYCOPROTEIN; GLYCOPROTEIN NMB; MELANIN; MONOCLONAL ANTIBODY; PARAFFIN; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; GLEMBATUMUMAB VEDOTIN; GPNMB PROTEIN, HUMAN; MEMBRANE PROTEIN; OLIGOPEPTIDE; VEDOTIN;

ADULT; AGED; ARTICLE; BIOTINYLATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENUCLEATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MELANOMA CELL; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UVEA MELANOMA; BIOSYNTHESIS; GENE EXPRESSION REGULATION; MELANOMA; METABOLISM; METASTASIS; MIDDLE AGED; ONCOLOGY; PROCEDURES; UVEA TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEDICAL ONCOLOGY; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; OLIGOPEPTIDES; UVEAL NEOPLASMS; IMMUNOCONJUGATES;

EID: 77952237462     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283364a08     Document Type: Article

References (23)

1. Strickland D, Lee JA. Melanomas of eye: stability of rates. Am J Epidemiol 1981;113:700-702.
2. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 2003;110:956-961. (Pubitemid 36560496)
3. Margo CE. The Collaborative Ocular Melanoma Study: an overview. Cancer Control 2004;11:304-309.
4. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 2003;110:962-965. (Pubitemid 36560497)
5. Triozzi PL, Eng C, Singh AD. Targeted therapy for uveal melanoma. Cancer Treat Rev 2008;34:247-258.
6. Singh AD, Wang MX, Donoso LA, Shields CL, De Potter P, Shields JA. Genetic aspects of uveal melanoma: a brief review. Semin Oncol 1996;23:768-772.
7. Weterman MA, Ajubi N, van Dinter IM, Degen WG, van Muijen GN, Ruitter DJ, et al. nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer 1995;60:73-81.
8. Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, et al. CR011, a fully human monoclonal antibody-auristatin e conjugate, for the treatment of melanoma. Clin Cancer Res 2006;12:1373-1382.
9. Doronina SO, Bovee TD, Meyer DW, Miyamoto JB, Anderson ME, Morris-Tilden CA, et al. Novel peptide linkers for highly potent antibodyauristatin conjugate. Bioconjug Chem 2008;19:1960-1963.
10. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-784.
11. McDonagh CF, Turcott E, Westendorf L, Webster JB, Alley SC, Kim K, et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng des Sel 2006;19:299-307.
12. Hwu P, Sznol M, Kluger H, Rink L, Kim KB, Papadopoulos N, et al. A phase i/ii study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma. J Clin Oncol 2008;26: (No 15s): 9029.
13. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003;44:4651-4659.
14. Ghilardi C, Chiorino G, Dossi R, Nagy Z, Giavazzi R, Bani M. Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics 2008;9:201.
15. Ripoll VM, Irvine KM, Ravasi T, Sweet MJ, Hume DA. Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol 2007;178:6557-6566.
16. Tomihari M, Hwang SH, Chung JS, Cruz PD Jr, Ariizumi K. Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion. Exp Dermatol 2009;18:586-595.
17. Shikano S, Bonkobara M, Zukas PK, Ariizumi K. Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. J Biol Chem 2001;276:8125-8134.
18. Qian X, Mills E, Torgov M, LaRochelle WJ, Jeffers M. Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate. Mol Oncol 2008;2:81-93.
19. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin e conjugate with potent and selective antitumor activity. Blood 2003;102:1458-1465.
20. Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006;12:2591-2596.
21. Hwu P, Sznol M, Pavlick A, Kluger H, Kim KB, Boasberg P, et al. A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma. J Clin Oncol 2009;27(No 15s): 9032.
22. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004;64:7205-7209.
23. Tschentscher F, Husing J, Holter T, Kruse E, Dresen IG, Jockel KH, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003;63:2578-2584.